Cortical accumulation of amyloid beta is one of the first events of Alzheimer’s disease pathophysiology, and has been suggested to follow a consistent spatiotemporal ordering, starting in the posterior cingulate cortex, precuneus and medio-orbitofrontal cortex. These regions overlap with those of the default mode network, a brain network also involved in memory functions. Aberrant default mode network functional connectivity and higher network sparsity have been reported in prodromal and clinical Alzheimer’s disease. We investigated the association between amyloid burden and default mode network connectivity in the preclinical stage of Alzheimer’s disease and its association with longitudinal memory decline. We included 173 participants, in which amyloid burden was assessed both in CSF by the amyloid beta 42/40 ratio, capturing the soluble part of amyloid pathology, and in dynamic PET scans calculating the non-displaceable binding potential in early-stage regions. The default mode network was identified with resting-state functional MRI. Then, we calculated functional connectivity in the default mode network, derived from independent component analysis, and eigenvector centrality, a graph measure recursively defining important nodes on the base of their connection with other important nodes. Memory was tested at baseline, 2- and 4-year follow-up. We demonstrated that higher amyloid burden as measured by both CSF amyloid beta 42/40 ratio and non-displaceable binding potential in the posterior cingulate cortex was associated with lower functional connectivity in the default mode network. The association between amyloid burden (CSF and non-displaceable binding potential in the posterior cingulate cortex) and aberrant default mode network connectivity was confirmed at the voxel level with both functional connectivity and eigenvector centrality measures, and it was driven by voxel clusters localized in the precuneus, cingulate, angular and left middle temporal gyri. Moreover, we demonstrated that functional connectivity in the default mode network predicts longitudinal memory decline synergistically with regional amyloid burden, as measured by non-displaceable binding potential in the posterior cingulate cortex. Taken together, these results suggest that early amyloid beta deposition is associated with aberrant default mode network connectivity in cognitively healthy individuals and that default mode network connectivity markers can be used to identify subjects at risk of memory decline.
Introduction

Cortical amyloid beta (Aβ) accumulation seems to be the first event of Alzheimer’s disease pathophysiological cascade and can be detected indirectly in CSF or directly through the visualization of Aβ fibrils on PET scans. It has been reported that CSF analysis is more sensitive than global amyloid PET in early Alzheimer’s disease stages, capturing the soluble part of amyloid pathology, crucial in the origin of synaptic pathology. Nonetheless, recent evidence suggests that Aβ deposition follows a consistent spatio-temporal order across the brain, making regional PET suitable for visualization of early Alzheimer’s disease pathology. Early Aβ-accumulating regions correspond to the posterior cingulate (PCC), precuneus and medial orbitofrontal (MOF) cortex. Such regions largely overlap with a functional brain network called the default mode network (DMN). It has been proposed that DMN disruptions might represent one of the early functional consequences associated with the molecular pathological processes underlying Alzheimer’s disease. Nonetheless, while aberrant DMN connectivity in Alzheimer’s dementia has been reported, studies investigating earlier stages of the Alzheimer’s disease continuum show conflicting results.

DMN areas show synchronous activity at resting-state functional magnetic resonance imaging (rs-fMRI) when an individual is awake but not involved in any specific mental activity. This is indirectly measured with independent component analysis (ICA) of blood oxygen level dependent (BOLD) signal, where local BOLD variability is interpreted as a proxy for variations in local neuronal activity and rs-fMRI functional connections are measured as synchronized BOLD signal variability between different brain regions in the absence of a task. The degree of co-activation of the network can be derived through
dual-regression and defined as functional connectivity (FC). Brain FC has been proposed to reflect the extent of neuronal metabolic activity. To elucidate further connectivity within the DMN, graph theoretical methods might be used. Specifically, eigenvector centrality (EC) reflects layers in the hierarchy of a network, recursively defining important nodes as those having more connections with other important nodes. EC might therefore be useful in localizing prominent hubs within the DMN through a hypothesis-free, data-driven method.

Regions of the DMN have been involved in memory retrieval, frequently impaired in Alzheimer’s disease individuals. An extensive body of literature identified memory as one of the earliest and most severely affected cognitive domains in Alzheimer’s disease. In line with this, we recently showed that amyloid pathology, measured with both CSF Aβ 42/40 ratio and PET binding potential, is associated with memory dysfunction in elderly cognitively healthy individuals, an association that was previously shown in later stages of Alzheimer’s disease.

With this in mind, we investigated whether early Aβ deposition, as defined both by CSF Aβ 42/40 ratio and PET [18F]flutemetamol non-displaceable binding potential (BPND) in early-stage regions, is associated with abnormal FC and EC within the DMN in a cohort of elderly cognitively intact individuals. As areas of the DMN are involved in memory circuits, and considering the association that we previously found between Aβ deposition and memory decline, we investigated whether FC within the DMN modifies the strength of this relation.

Materials and methods

Study participants

Study participants were selected from the European Information Framework for Alzheimer’s Disease (EMIF-AD)-PreclinAD study. Inclusion criteria were the following: age between 60 and 100, normal cognition as assessed by a delayed recall score >−1.5 SD of demographically adjusted normative data on the Consortium to Establish a Registry for Alzheimer’s Disease 10 word list, a Telephone Interview for Cognitive Status modified score ≥23, a 15-item Geriatric Depression Scale score of <11 and a Clinical Dementia Rating score of 0. Individuals were excluded if they presented any significant medical, neurological or psychiatric condition potentially affecting cognitive performance or MRI contraindications. A total of 204 subjects were included in the EMIF-AD PreclinAD study. A subset of 190 subjects had both T1-weighted and rs-fMRI scans available. Seventeen individuals were excluded due to lack of sufficient good-quality images, resulting in a total of 173 individuals. We defined amyloid status using either visual read of dynamic [18F]flutemetamol PET images or CSF Aβ/42/40 ratio (ADx Neurosciences/Euroimmun assays) <0.066 (based on Gaussian mixture modelling).

Neuropsychological assessment

Longitudinal neuropsychological data were retrieved at two follow-up time points for subsets of 165 and 94 participants respectively (mean follow-up 1 duration 23 ± 3 months; mean follow-up 2 duration 50 ± 3 months; mean difference between follow-up time points 26 ± 2 months). Our sample comprised cognitively healthy individuals, thus detecting incipient cognitive dysfunction was not trivial. In light of this, we chose to focus on the memory domain as lower memory was previously associated with higher Aβ in this cohort. We generated baseline and follow-up memory composite scores by using the total immediate recall and delayed recall of the Dutch version of the Rey Auditory Verbal Learning test (RAVLT), the 3- and 20-minute recall of the Rey Complex Figure (RCF), the total score from the Face Name Associated Memory Examination (FNAME)-names and occupations delayed recall. Composite scores were only computed for participants with at least four test scores. All test scores were z-transformed using the baseline mean and standard deviation of the total sample (NEMIF-AD PreclinAD = 204), and combined into one composite score. Memory slopes were calculated as the difference between follow-up and baseline composite scores, divided by time between measurements.

Cerebrospinal fluid

Lumbar puncture was performed between 10 AM and 2 PM, after at least 2 h of fasting, using Sarstedt polypropylene syringes and a Spinocan 23 Gauge needle. Up to 20 mL CSF was obtained from 109 (63%) study participants. CSF samples were centrifuged at 1300–2000 g at 4°C for 10 min and supernatants were stored in Sarstedt aliquots of 0.5 mL at −80°C until analysis. A maximum of 2 h was allowed between lumbar puncture and freezing. Aβ 42/40 ratio levels were analysed at the Neurochemistry Laboratorium of the Amsterdam UMC by personnel blinded to clinical information using ADx Neurosciences/Euroimmun kits from the same batch, according to the manufacturer instructions.

MRI and PET acquisition

Whole-brain MRI and PET scans were acquired at Amsterdam University Medical Center, location VUMc, using a 3 T Philips Ingenuity Time-of-Flight PET/MRI scanner (Philips Healthcare, Cleveland, USA) with an 8-channel head coil. High-resolution isotropic structural 3D T1-weighted images were acquired using a sagittal turbo field echo sequence (1.00 mm3 isotropic voxels, repetition time = 7.9 ms, echo time = 4.5 ms and flip angle = 8°). Whole brain rs-fMRI scans were acquired using a fast field
echo-planar imaging (EPI) sequence (repetition time (TR) = 1800 ms; echo time (TE) = 35 ms; flip angle (FA) = 80°; matrix = 64 × 64; field of view (FOV) = 221 mm; voxel size = 3.3 mm × 3.3 mm × 3.0 mm). In total, 33 axial AP-oriented slices were acquired in interleaved order, resulting in a total of 202 volumes. During the rs-fMRI scan, light and music were turned off and participants were instructed to keep their eyes closed, remain awake, and not think to anything in particular. All MRI scans were visually assessed by an experienced neuroradiologist for incidental findings.

Dynamic [18F]Flutemetamol amyloid-PET scans were performed according to a dual-time window acquisition protocol with 30 min scans acquired immediately after manual tracer injection (dose: 191 ± 20 MBq), followed by a 60 min break, and then a second scan of 20 min (i.e. 90–110 min post injection) (for further details see Konijnenberg et al.32). A 3D T1-weighted gradient echo pulse MR image was acquired prior to each PET scan for attenuation correction.

**MRI analysis**

Grey matter (GM) volume, normalized for head size, was estimated using SIENAX,47 part of FMRIB’s Software Library (FSL Version 5.0.4; www.fmrib.ox.ac.uk/fsl Accessed 15 September 2021).48

Preprocessing of rs-fMRI scans was also performed using the FSL pipeline (FSL Version 5.0.4; www.fmrib.ox.ac.uk/fsl Accessed 15 September 2021) and it consisted of motion correction,49 removal of non-brain tissue,50 spatial smoothing by using a Gaussian kernel of 5 mm full width at half maximum (FWHM) to reduce noise, and high-pass temporal filtering to remove low-frequency artefacts. After preprocessing, affine registration was used to register rs-fMRI images to 3D T1-weighted images. Subsequently, the images were registered to the whole time series, to balance brain coverage and preservation of network topology. EC values inside the previously defined DMN mask were computed (Fig. 1).

ICA and EC methods have been chosen as they give voxelwise reports and they are robust against multiple sources of variability in resting-state fMRI analyses.20,25

**PET analysis**

PET scans were reconstructed by applying the LOR-RAMLA dedicated Philips reconstruction algorithm for the brain. The first emission scans were reconstructed into 18 frames with increasing time length (6 × 5, 3 × 10, 4 × 60, 2 × 150, 2 × 300, 1 × 600 s), while the second scan was reconstructed into 4 frames of 300 s each. Obtained PET images were preprocessed with Vinci Software version 2.56 (http://vinci.sf.mpg.de/ Accessed 15 September 2021). using its multimodality setting of Vinci for co-registration of dynamic scans with individual’s T1-weighted MRI sequences. Regions of interest (ROIs) were automatically delineated based on the T1-weighted MRI images using PVElab.59,60 Parametric non-displaceable binding potential (BPND) was calculated by using the receptor parametric mapping (RPM) implementation of the Simplified Reference Tissue Model (SRTM) in PPET.36,61,62 Cerebellar GM was chosen as the reference region. For analyses, distribution volume ratio (DVR) was calculated as a measure of receptor availability for radioligand (BPND + 1) and ROIs identified using Desikan–Killian atlas.63
Statistical analyses

Each 3D subject-specific DMN connectivity map, resulting from dual regression, was averaged inside the mask of their corresponding DMN. FC values in each subject’s DMN had been log-transformed to correct for a skewness in their distribution. Resulting output were mean FC and voxelwise FC within the DMN per subject, which were then used for statistical analyses.

Aβ was used as a continuous measure and was defined as CSF Aβ 42/40 ratio or PET BP ND in early-stage Alzheimer’s disease regions, i.e. the PCC, precuneus, and MOF cortex. Aβ, log FC and normalized GM volume values were transformed to z-scores.

Four models tested the relationship between Aβ burden and average FC in the DMN; one for each quantitative measure of Aβ. We used generalized estimating equations (GEE), using family ID (indication of twin pairs) as a random factor, to correct for correlated observations in monozygotic twins, and including age, sex and normalized GM volume as covariates.

To gain additional information on the effect of Aβ on DMN FC and EC, a voxelwise GEE analysis was performed in the DMN mask voxels, correcting for the familial clustering of twin pairs, as well as confounders, such as age, sex and normalized GM volume. Of the clusters of voxels with P-value < 0.05, we selected the clusters with a minimum cluster extent of 10 voxels. To elucidate the role of FC in relation to memory decline, we tested whether FC in the DMN at baseline was predictive of longitudinal memory decline using GEE, correcting for age at the time of examination, sex, years of education, and using family ID as a random factor. Furthermore, given the known relationship between Aβ deposition and memory decline, we also built a three-way interaction model which also included Aβ burden. All the statistical analyses were conducted in R version 3.6.0 (R Foundation for Statistical Computing, Vienna, Austria).

Data availability

Data requests can be submitted via the EMIF-AD Catalogue (see http://www.emif.eu/emif-ad-2/ Accessed 15 September 2021).
Results

Study sample

Demographics, clinical and imaging characteristics of the study participants are summarized in Table 1. The mean age of the population was 70.3 ± 7.4 years and the mini-mental state examination (MMSE) average was 29.0 ± 1.2, supporting that the population was cognitively unimpaired. CSF data were analysed for 109 out of the 173 study participants, while PET BPND could be estimated in a subset of 167 individuals. The amyloid burden was generally low, as expected in this cognitively normal cohort (amyloid positive, 17%). In line with the literature, amyloid positive individuals were generally older (P-value = 0.001) and had a slightly lower performance at neuropsychological tests (Table 1).

The results of follow-up memory tests are summarized in Table 2. On a group level, performance on RAVLT immediate and delayed recall decreased on follow-up. A learning effect was instead registered for the 3 min and 20 min RCF tests, and for the FNAME delayed recall subscores.

The relationship between amyloid burden and DMN connectivity

An inverse relationship was found between Aß burden and FC in the DMN when Aß was defined by CSF Aß 42/40 ratio (ß = 0.17, P-value = 0.020) and by PET BPND in the PCC (ß = −0.15, P-value = 0.006), but not with amyloid burden defined by PET BPND in the MOF and in the precuneus (MOF: ß = −0.09, P-value = 0.153; precuneus: ß = −0.09, P-value = 0.165) (Table 3).

We then investigated at a voxelwise level how FC and EC values within the DMN changed as a function of amyloid burden as defined by the amyloid metrics that showed a significant relationship between mean FC in the DMN, i.e. Aß 42/40 ratio and PET BPND in the PCC. Higher amyloid burden corresponded to lower FC and EC in voxels within the DMN, after correcting for age, sex, normalized GM volume and twin status (Table 4). Voxel clusters that significantly associated with early-stage Aß pathology were localized in the precuneus, cingulate gyrus, and angular gyrus both for the FC and EC measures, and also in the middle cingulate gyrus for EC measures (Fig. 2).

The relationship between FC in the DMN and longitudinal memory decline

Next, we determined the impact that alterations in the DMN FC have on longitudinal memory decline through two-way and three-way interaction analyses. We found that baseline FC in the DMN was predictive of longitudinal memory decline independent of amyloid burden (Table 5). Moreover, our three-way interaction analysis showed a significant interaction between DMN FC and

Table 1 Description of the study participants at baseline.

<table>
<thead>
<tr>
<th>Demographics and clinical characteristics</th>
<th>Total group (n = 173)</th>
<th>Amyloid negative (83%)</th>
<th>Amyloid positive (17%)</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td>70.3 ± 7.4</td>
<td>69.3</td>
<td>74.1</td>
<td>0.010</td>
</tr>
<tr>
<td>Sex, n females (%)</td>
<td>100 (57.8%)</td>
<td>78 (55.3%)</td>
<td>19 (65.5%)</td>
<td>0.421</td>
</tr>
<tr>
<td>Education (years)</td>
<td>11.6 ± 2.7</td>
<td>11.7 ± 2.6</td>
<td>11.1 ± 3.4</td>
<td>0.489</td>
</tr>
<tr>
<td>MMSE</td>
<td>29.0 ± 1.2</td>
<td>29.1 ± 1.1</td>
<td>28.6 ± 1.5</td>
<td>0.117</td>
</tr>
<tr>
<td>Neuropsychological tests</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>RAVLT immediate recall (n = 164)</td>
<td>42.1 ± 9.0</td>
<td>42.8 ± 9.1</td>
<td>38.8 ± 7.8</td>
<td>0.06</td>
</tr>
<tr>
<td>RAVLT delayed recall (n = 164)</td>
<td>8.4 ± 2.8</td>
<td>8.5 ± 2.9</td>
<td>7.8 ± 2.2</td>
<td>0.112</td>
</tr>
<tr>
<td>RCF recall 3 min (n = 165)</td>
<td>18.8 ± 5.3</td>
<td>19.5 ± 5.3</td>
<td>15.6 ± 4.1</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>RCF recall 20 min (n = 163)</td>
<td>18.7 ± 4.9</td>
<td>19.2 ± 4.8</td>
<td>16.0 ± 4.2</td>
<td>0.038</td>
</tr>
<tr>
<td>FNAME delayed recall subscore names (n = 150)</td>
<td>20.1 ± 9.9</td>
<td>21.0 ± 10.2</td>
<td>15.6 ± 6.7</td>
<td>0.397</td>
</tr>
<tr>
<td>FNAME delayed recall subscore occupation (n = 150)</td>
<td>33.2 ± 8.9</td>
<td>33.9 ± 8.8</td>
<td>29.8 ± 9.1</td>
<td>0.163</td>
</tr>
<tr>
<td>MRI imaging characteristics</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>GM volume (cm³)</td>
<td>72693 ± 8574</td>
<td>73260 ± 7403</td>
<td>72262 ± 4352</td>
<td>0.275</td>
</tr>
<tr>
<td>Log FC in the DMN</td>
<td>1.36 ± 0.14</td>
<td>1.36 ± 0.13</td>
<td>1.34 ± 0.13</td>
<td>0.209</td>
</tr>
<tr>
<td>Amyloid status</td>
<td>0.10 ± 0.03</td>
<td>0.11 ± 0.02</td>
<td>0.05 ± 0.02</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>CSF Aß 42/40 ratio (pg/ml) (n = 109)</td>
<td>1.03 ± 0.13</td>
<td>0.99 ± 0.08</td>
<td>1.20 ± 0.16</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>PET Global DVR (n = 167)</td>
<td>1.36 ± 0.19</td>
<td>1.30 ± 0.11</td>
<td>1.64 ± 0.24</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>PET DVR in the precuneus (n = 167)</td>
<td>1.21 ± 0.16</td>
<td>1.17 ± 0.09</td>
<td>1.44 ± 0.22</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>PET DVR in the MOF cortex (n = 167)</td>
<td>1.21 ± 0.18</td>
<td>1.15 ± 0.08</td>
<td>1.50 ± 0.23</td>
<td>&lt;0.001</td>
</tr>
</tbody>
</table>

Data are presented as mean ± SD for continuous variables, or number (percentage) for dichotomous variables. All, amyloid β; DMN, default-mode network; DVR, distribution volume ratio; FC, functional connectivity; FNAME, face-name associated memory examination; GM, gray matter; MMSE, mini-mental state examination; MOF, medio-orbitofrontal cortex; PCC, posterior cingulate cortex; RAVLT, Rey auditory verbal learning test; RCF, Rey complex figure.
**Table 2** Results of follow-up neuropsychological tests

<table>
<thead>
<tr>
<th>Neuropsychological tests</th>
<th>Follow-up 1</th>
<th>Follow-up 2</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>N</td>
<td>Mean ± SD</td>
</tr>
<tr>
<td>RAVLT immediate recall</td>
<td>165</td>
<td>39.7 ± 9.1</td>
</tr>
<tr>
<td>RAVLT delayed recall</td>
<td>165</td>
<td>7.7 ± 2.9</td>
</tr>
<tr>
<td>RCF recall 3 min</td>
<td>164</td>
<td>19.7 ± 5.8</td>
</tr>
<tr>
<td>RCF recall 20 min</td>
<td>164</td>
<td>19.7 ± 5.5</td>
</tr>
<tr>
<td>FNAME delayed recall</td>
<td>154</td>
<td>21.5 ± 11.0</td>
</tr>
<tr>
<td>FNAME delayed recall</td>
<td>154</td>
<td>33.4 ± 7.8</td>
</tr>
</tbody>
</table>

FNAME, face-name associated memory examination; RAVLT, Rey auditory verbal learning test; RCF, Rey complex figure.

**Table 3** Association of mean FC in the DMN and amyloid burden

<table>
<thead>
<tr>
<th>Regression coefficient (β)</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>CSF Aβ42/40 ratio</td>
<td>0.17</td>
</tr>
<tr>
<td>BPND in the PCC</td>
<td>-0.15</td>
</tr>
<tr>
<td>BPND in precuneus</td>
<td>-0.09</td>
</tr>
<tr>
<td>BPND in MOF cortex</td>
<td>-0.09</td>
</tr>
</tbody>
</table>

All values were transformed to z-scores. All GEE analyses took into account family ID as a random factor and were corrected for age, sex, and normalized GM volume.

**Table 4** Voxel clusters that showed a significant association between amyloid burden (defined as Aβ42/40 ratio and DVR in PCC) and FC and EC measures within the DMN

<table>
<thead>
<tr>
<th>Voxels</th>
<th>Brain area</th>
<th>Beta</th>
<th>Coordinate points</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>x</td>
<td>y</td>
<td>z</td>
</tr>
<tr>
<td>FC in DMN</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Aβ42/40 ratio</td>
<td>423</td>
<td>Left cingulate gyrus</td>
<td>0.004</td>
<td>21</td>
</tr>
<tr>
<td></td>
<td>40</td>
<td>Right angular gyrus</td>
<td>0.004</td>
<td>31</td>
</tr>
<tr>
<td></td>
<td>12</td>
<td>Right precuneus</td>
<td>0.003</td>
<td>37</td>
</tr>
<tr>
<td>BPND in PCC</td>
<td>194</td>
<td>Left precuneus</td>
<td>-0.003</td>
<td>20</td>
</tr>
<tr>
<td></td>
<td>116</td>
<td>Left angular gyrus</td>
<td>-0.003</td>
<td>11</td>
</tr>
<tr>
<td></td>
<td>46</td>
<td>Right angular gyrus</td>
<td>-0.002</td>
<td>32</td>
</tr>
<tr>
<td></td>
<td>15</td>
<td>Left precuneus</td>
<td>-0.003</td>
<td>18</td>
</tr>
<tr>
<td>EC in DMN</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Aβ42/40 ratio</td>
<td>67</td>
<td>Left precuneus</td>
<td>0.004</td>
<td>17</td>
</tr>
<tr>
<td></td>
<td>40</td>
<td>Right precuneus</td>
<td>0.003</td>
<td>30</td>
</tr>
<tr>
<td></td>
<td>12</td>
<td>Right cingulate gyrus</td>
<td>0.003</td>
<td>22</td>
</tr>
<tr>
<td></td>
<td>11</td>
<td>Right cingulate gyrus</td>
<td>0.003</td>
<td>25</td>
</tr>
<tr>
<td></td>
<td>11</td>
<td>Left middle temporal gyrus</td>
<td>0.003</td>
<td>7</td>
</tr>
<tr>
<td>BPND in PCC</td>
<td>23</td>
<td>Right cingulate gyrus</td>
<td>-0.003</td>
<td>25</td>
</tr>
<tr>
<td></td>
<td>17</td>
<td>Left precuneus</td>
<td>-0.002</td>
<td>16</td>
</tr>
<tr>
<td></td>
<td>15</td>
<td>Right angular gyrus</td>
<td>-0.002</td>
<td>31</td>
</tr>
</tbody>
</table>

Models are corrected for age, sex, normalized GM volume and twin status. P-values are FWE-corrected.

Aβ, amyloid β; BPND, non-displaceable binding potential; DMN, default-mode network; DVR, distribution volume ratio; FC, functional connectivity; FWE, family-wise error; PCC, posterior cingulate cortex; FWE, family-wise error.

**Discussion**

In this study, we investigated the relation between Aβ deposition and connectivity within the DMN in a cohort of cognitively healthy elderly individuals. We found that amyloid burden as defined by CSF Aβ 42/40 ratio and PET binding potential in the PCC is predictive of lower FC in the DMN. Furthermore, we showed that alterations of FC and EC measures as a function of Aβ deposition are strongest in voxel clusters localized in the precuneus, cingulate gyrus, angular gyrus and left middle temporal gyrus. Finally, we demonstrated that FC in the DMN is predictive of longitudinal memory decline, and its effect is synergistic with that of Aβ as defined by PET BPND in PCC.

This study demonstrates that early-stage Aβ accumulation as determined by regional PET amyloid deposition, namely in the PCC, is associated with aberrant DMN connectivity in a cognitively healthy population. We also show voxelwise FC and EC alterations in the DMN of early Aβ accumulators, offering a more detailed topographical overview of Aβ-dependent DMN changes. Our results expanded the body of literature regarding the association between Aβ deposition and aberrant DMN connectivity76–77 and subjective cognitive decline78—to cognitively healthy individuals with generally low amyloid burden. Moreover, we showed that localized Aβ accumulation in PCC has a synergistic effect with DMN connectivity in predicting longitudinal memory decline.

The mechanism through which Aβ deposition affects DMN connectivity remains still unclear. Pascoal et al. suggested that Aβ toxic effect is mediated by a local...
reduction in metabolism in vulnerable neurons. The repercussions of such a phenomenon in the DMN can be indirect, affecting regions that are functionally connected with the DMN, or direct, if Aβ deposition topographically overlaps with DMN areas. Metabolic stress might thus be the result of the large fluctuations of neuronal firing in these brain areas, which might be fueled by the toxic effect of Aβ and, on the other hand, could stimulate further Aβ accumulation through a positive feedback mechanism, eventually resulting in neuronal death.

The results of our voxelwise analyses provide evidence in support of the direct effect of Aβ plaques on neuronal metabolism, as FC and EC alterations in the DMN are associated with higher Aβ deposition in the PCC. This is in line with other studies showing topographical overlap within the DMN regions of Aβ deposition, disrupted FC, hypometabolism, and atrophy in more advanced disease stages.

Voxels that showed hypoconnectivity (as indicated by FC), higher sparsity and lower relative importance (as indicated by EC) of the DMN as a response to early-stage Aβ accumulation were localized in cingulate gyrus, angular gyrus, precuneus and middle temporal gyrus. Such regions demonstrate prominent atrophy in individuals further along the Alzheimer’s disease continuum. In particular, the PCC is an important hub of the medial temporal memory circuit, together with the hippocampus and entorhinal cortex. Pathological and imaging studies have reported Aβ deposition, a lower number of synaptic connections, hypometabolic activity and lower FC in the...
PCC of individuals with prodromal Alzheimer’s disease and Alzheimer’s dementia.\cite{10,5,7,5,8,8,9,90} Our results confirm the central role of the PCC in Alzheimer’s disease, further extending the concept to the earliest phases of Aβ accumulation in cognitively healthy individuals,\cite{8} as we show both early Aβ deposition and aberrant connectivity in this area.

Not only do our findings indicate that DMN areas are vulnerable to Alzheimer’s pathology, but they also suggest that DMN connectivity influences the rate of memory decline both independently and as a function of amyloid burden as measured with PET BP\textsubscript{ND} in PCC. We did not find that DMN FC modified the association between CSF Aβ 42/40 ratio and memory, possibly due to the different sensitivity of these measures.\cite{9} Taken together, these findings suggest that the effect of early Aβ accumulation on cognition might depend on neuronal vulnerability, which can in turn be quantified through FC and EC in the DMN. Our findings are in line with previous works in the literature, showing that amyloid-related alterations of brain FC appear before or together with cognitive alterations.\cite{91} This could raise some questions regarding the definition of cognitively normal individuals in previous studies, as suggested by Brier \textit{et al.}, but the discussion of this issue is beyond the scope of this study.\cite{92}

The measures used for our analyses were defined based on different, possibly complementary, modalities. Specifically, amyloid burden was measured both through CSF (Aβ 42/40 ratio) and amyloid PET (BP\textsubscript{ND} in the PCC, precuneus, and MOF cortex) analyses. Similarly, we assessed DMN connectivity with two different measures, \textit{i.e.} FC derived from ICA and EC. The definition of markers through multiple modalities (Aβ), different analytic techniques (rs-fMRI metrics), and composite scores (memory) and the inclusion of continuous biomarkers are methodological strengths of our study. Nevertheless, some methodological concerns should be addressed. Our sample is not totally representative of the general population, as it is mostly composed of highly educated white Caucasians, generally missing minorities. Moreover, our effect sizes were modest, probably due to the composition of our cohort, which was generally healthy and with a low amyloid burden, and to the fact that DMN FC and EC are indirect measures of brain hypometabolism. Still, we believe that this work shows strong evidence in support of the role of the DMN in Aβ-related changes, indicating that aberrant DMN connectivity likely mirrors early neurodegenerative processes.

In conclusion, we found that cognitively healthy individuals show disrupted connectivity and higher network disorganization and sparsity within the DMN as a function of incipient Aβ accumulation. Moreover, FC within the DMN predicts longitudinal memory decline, suggesting that DMN connectivity might explain different trajectories of decline in individuals early along the Alzheimer’s disease continuum, both independently of amyloid deposition and synergistically with regional amyloid deposition in the PCC. Taken together, these findings suggest that DMN plays an important role in early-stage Alzheimer’s disease pathology, and consequently DMN connectivity is an interesting marker for the diagnostic and prognostic assessment of individuals in the earliest stages of Alzheimer’s disease.

**Acknowledgements**

The authors would like to express their gratitude to all the EMIF-AD project participants for their efforts to join and complete this demanding study, without whom this research would have not been possible. Moreover, we would like to thank our colleagues of the Netherlands Twin Register for referring participants.

**Funding**

This project has received support from the following European Union/European Federation of Pharmaceutical Industries and Associations (EU/EFPIA) Innovative Medicines Initiatives 1 and 2 Joint Undertakings: European Prevention of Alzheimer’s Dementia (EPAD) grant No 115736, Amyloid Imaging to prevent Alzheimer’s disease (AMYPAD) grant No 115952, European Medical Information Framework (EMIF) grant No 115372. F.B. was supported by the National Institute for Health Research (NIHR) biomedical research centre at University College London Hospital (UCLH). F.B. and A.M.W. are supported by the European Union’s Horizon 2020 research and innovation programme under grant agreement no. 666992. Research of CET is supported by the European Commission (Marie Curie International Training Network, EU Joint Programme—Neurodegenerative Disease research), Health Holland, the Dutch Research Council—Zorg Onderzoek Nederland and the area Medical Sciences—ZonMW, The Weston Brain Institute, Alzheimer Netherlands, and Alzheimer Association. This work received in kind sponsoring of the CSF assay from ADx NeuroSciences and Euroimmun, and the PET-tracer [18F]flutemetamol from GE Healthcare. The Netherlands Twin Register receives funding from the Netherlands Organization for Scientific Research to maintain the Nederlands Tweelingen Register (NTR) repository [Nederlandse Organisatie voor Wetenschappelijk Onderzoek (NOW)-Groot 480-15-001/674].

**Conflict of interests**

P.S. received grants from GE Healthcare, Piramal and Merck, paid to his institution; he has received speaker’s fees paid to the institution Alzheimer Center, VU University Medical Center, Lilly, GE Healthcare, and Roche. B.N.M.v.B. received research support from ZON-MW, AVID radiopharmaceuticals, CTMM and Janssen...
Pharmaceuticals. B.N.m.v.B. is a trainer for Piramal and GE; he receives no personal honoraria. F.B. is a consultant to Bayer, Biogen, Merck, Roche, IXICO Ltd, GeNeuro and Combinostics and receives research support from EU/EFPIA Innovative Medicines Initiative Joint Undertaking (AMYPAD consortium), EuroPOND (H2020d), UK MS Society, NIHR UCLH Biomedical Research Centre (BRC) and ECTRIMS-MAGNIMS. C.E.T. has a collaboration contract with Adx Neurosciences and Quanterix, performed contract research or received grants from AxonNeurosciences, Biogen, Boehringer, Brainstorm Therapeutics, Celgene, EIP farma, Esai, Janssen prevention center, Roche, Toyama, Vivoryon. A.M.W. receives research support from EU/EFPIA Innovative Medicines Initiative Joint Undertaking (EPAD and AMYPAD consortia) and EuroPOND (H2020d). S.I. receives research support from EU/EFPIA Innovative Medicines Initiative Joint Undertaking (EPAD consortium). Other authors declare that they have no competing interests.

References


